Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Pfizer | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Pfizer

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer

4Q Revenues: $12.6 billion (flat)

4Q Earnings: $9.4 billion (earnings were $2.7 billion 4Q2005)

FY Revenues: $48.4 billion (+2%)

FY Earnings: $19.3 billion (earnings were $8 billion FY2005)

Comments: Worldwide pharmaceutical revenues were $45.1 billion for the year, up 2%, and were flat at $11.7 billion for the quarter. U.S. revenues were $6.1 billion, down 3%, reflecting the loss of exclusivity of Zoloft in the U.S. in June 2006. Lipitor sales were flat at $3.3 billion in the quarter, and up 6% to $12.9 billion for the year. Nine products exceeded $1 billion in sales in 2006, with Detrol and Lyrica joining this list for the first time. Detrol sales for the year were $1.1 billion, up 11%. Lyrica sales were $1.2 billion, up from $291 million FY2005. R&D expenses were up 22% to $2.4 billion for the quarter and up 5% to $7.6 billion for the year. Earnings for the quarter and FY include significant gains from discontinued operations and the sale of the Consumer Healthcare Business. In the quarter, the company submitted filings with the FDA for Lyrica for Fibromyalgia and for Maraviroc.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters